SCHEMBL1075261

SCHEMBL1075261

CC(CC(C)(C)C)OC(C)CC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.40
HRH3 Q9Y5N1 1/20 0.32
MCHR1 Q99705 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19479070 0.88 MAPK1 (0.30) MAPK1HRH3
SCHEMBL28610109 0.80 HRH3 (0.32) HRH3MCHR1
SCHEMBL18025231 0.79 HRH3 (0.36) HRH3
SCHEMBL11938124 0.78
SCHEMBL17708098 0.78
SCHEMBL18254224 0.78
SCHEMBL24974724 0.78
SCHEMBL16316437 0.75
SCHEMBL11922164 0.75 MAPK1 (0.31) MAPK1HRH3
SCHEMBL7752093 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4128392-A1 LITHIUM-ION BATTERY WITH ANODE COMPRISING BLEND OF INTERCALATION-TYPE ANODE MATERIAL AND CONVERSION-TYPE ANODE MATERIAL Sila Nanotechnologies Inc. (US) 2023-02-08 EP disclosed
US-20210313617-A1 LITHIUM-ION BATTERY WITH ANODE COMPRISING BLEND OF INTERCALATION-TYPE ANODE MATERIAL AND CONVERSION-TYPE ANODE MATERIAL SILA NANOTECHNOLOGIES, INC. 2021-10-07 US disclosed
WO-2021203086-A1 LITHIUM-ION BATTERY WITH ANODE COMPRISING BLEND OF INTERCALATION-TYPE ANODE MATERIAL AND CONVERSION-TYPE ANODE MATERIAL SILA NANOTECHNOLOGIES INC. (US) 2021-10-07 WO disclosed
US-20160237302-A1 WATERBORNE COMPOSITIONS CALLAGHAN INNOVATION RESEARCH LIMITED (NZ) 2016-08-18 US disclosed
EP-2065387-B1 Quartz glass micro-photoreactors and synthesis of 10-hydroxycamptothecin and 7-alkyl-10-hydroxycamptothecin HERAEUS GMBH W C (DE) 2011-01-19 EP disclosed
EP-2065387-A2 Quartz glass micro-photoreactors and synthesis of 10 hydroxycamptothecin and 7-alkyl-10-hydroxycamptothecin W.C. Heraeus GmbH (DE) 2009-06-03 EP disclosed
US-7276505-B2 Immunomodulating heterocyclic compounds MEDIGENE LIMITED (GB) 2007-10-02 US disclosed
US-20070021428-A1 Immunomodulating heterocyclic compounds AVIDEX LIMITED (GB) 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021428-A1 Immunomodulating heterocyclic compounds CD40, CD40LG, NGFR MAPK1 2194/4885HRH3 34/4885MCHR1 738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.